GEn1E Lifesciences

GEn1E Lifesciences, formerly known as Gen1E Lifesciences, operates out of Palo Alto, CA, and is actively engaged in the healthcare industry, specifically focusing on therapeutics. The company has made significant strides in drug development by leveraging its AI/ML platform, RIDGE™, which covers the entire process from discovery to clinical studies. This platform employs advanced techniques such as neural networks, gradient boosting methods, and hidden Markov models to expedite the development process. GEn1E Lifesciences has successfully accelerated a lead compound from early discovery to Phase 2 within just 2.5 years using seed capital. Additionally, the company utilizes disease mapping databases to explore further indications for its drugs, thereby expanding the potential treatment spectrum. GEn1E has built a pipeline targeting 3 therapeutic areas across 2 different targets and plans to advance 2 additional indications to Investigational New Drug (IND) status in the next 12 months through its super-efficiency model. The company’s partners include notable organizations such as Vituity, BARDA, and Inflect Health. GEn1E Lifesciences has also been recognized for its innovative approach in drug development, winning the UCSF Health Hub Digital Health Award.